Five-fraction breast RT is established for WBI and APBI, while RNI evidence matures
Five-fraction RT is well supported for selected whole- and partial-breast treatment, while regional nodal and postmastectomy evidence remains less mature.
Five-fraction RT is well supported for selected whole- and partial-breast treatment, while regional nodal and postmastectomy evidence remains less mature.
Across 478 patients, hypofractionated proton re-irradiation showed encouraging site-specific outcomes, but heterogeneous retrospective evidence prevents firm conclusions on efficacy or safety.
A systematic review argues that α/β is disease- and context-specific rather than a fixed biological constant across radiotherapy settings.
Concurrent and consolidation ICI produced similar pathological response rates once analyses were restricted to neoadjuvant chemoradiotherapy studies.
Acral melanoma has an immune-cold phenotype and weaker ICI responsiveness; radiotherapy-based immune priming is biologically plausible but clinically unproven.
Reported atrial fibrillation occurred in 7.6% after thoracic radiotherapy when cohorts with substantial perioperative confounding were excluded.
SBRT can provide high local control in selected oligometastatic pancreatic cancer, but randomized survival evidence and patient-selection criteria remain limited.
Contemporary evidence supports contralateral parotid mean dose as the most robust xerostomia predictor, with risk rising around 24–26 Gy.
Across 14 studies, repeat stereotactic radiotherapy achieved 76% one-year local control, but symptomatic radiation necrosis occurred in 10%.
Across 12 retrospective studies, radiotherapy achieved 67–100% fistula-control rates, often with cumulative doses of only a few gray.
Ten contemporary multimodal deep-learning studies showed inconsistent external performance, calibration and reporting, limiting clinical use of personalized toxicity prediction.
Across 127 studies, CBCT-guided online adaptation repeatedly improved target coverage and OAR sparing, while evidence for better clinical outcomes remained sparse.
No prospective trial has established the safety of combining partial breast irradiation with sentinel lymph node biopsy omission in early breast cancer.
This review argues against a universal TBI dose, emphasizing conditioning intensity, chemotherapy backbone, disease biology and patient fitness.
Modern proton techniques reduce cardiopulmonary dose and can control skin exposure, while randomized cardiac and cancer-control endpoints remain pending.